Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Intravitreal ranibizumab as primary treatment for neovascular membrane associated with idiopathic juxtafoveal retinal telangiectasia.

× No keyword cloud information.

8 in total

1. Neovascular membranes associated with idiopathic juxtafoveolar telangiectasis.

Authors: Nicholas E Engelbrecht; Thomas M Aaberg; Jennie Sung; Mary Lou Lewis
Journal: Arch Ophthalmol Date: 2002-03

2. Surgical removal of subfoveal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.

Authors: A S Berger; B W McCuen; G C Brown; R L Brownlow
Journal: Retina Date: 1997 Impact factor: 4.256

3. Idiopathic macular telangiectasia.

Authors: Lawrence A Yannuzzi; Anne M C Bardal; K Bailey Freund; Kuan-Jen Chen; Chiara M Eandi; Barbara Blodi
Journal: Arch Ophthalmol Date: 2006-04

4. Intravitreal bevacizumab (Avastin) associated with the regression of subretinal neovascularization in idiopathic juxtafoveolar retinal telangiectasis.

Authors: Rodrigo Jorge; Rogério A Costa; Daniela Calucci; Ingrid U Scott
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2006-11-29 Impact factor: 3.117

5. Bevacizumab (avastin) therapy for idiopathic macular telangiectasia type II.

Authors: Jaclyn L Kovach; Philip J Rosenfeld
Journal: Retina Date: 2009-01 Impact factor: 4.256

6. Photodynamic therapy of subfoveal neovascular membrane in type 2A idiopathic juxtafoveolar retinal telangiectasis.

Authors: Bernadette Snyers; Claire Verougstraete; Laurence Postelmans; Anita Leys; Philip Hykin
Journal: Am J Ophthalmol Date: 2004-05 Impact factor: 5.258

7. Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia.

Authors: Pukhraj Rishi; Daraius Shroff; Ekta Rishi
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2008-01-12 Impact factor: 3.117

8. Intravitreal bevacizumab (Avastin) for subretinal neovascularization secondary to type 2A idiopathic juxtafoveal telangiectasia.

Authors: Subrata Mandal; Pradeep Venkatesh; Zahir Abbas; Rajpal Vohra; Satpal Garg
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2007-03-08 Impact factor: 3.117

8 in total

6 in total

1. Treatment of nonneovascular idiopathic macular telangiectasia type 2 with intravitreal ranibizumab: results of a phase II clinical trial.

Authors: Brian C Toy; Euna Koo; Catherine Cukras; Catherine B Meyerle; Emily Y Chew; Wai T Wong
Journal: Retina Date: 2012-05 Impact factor: 4.256

2. Intravitreal anti-VEGF treatment for subretinal neovascularisation secondary to type 2 idiopathic juxtafoveolar telangiectasia.

Authors: Teresa Barth; Florian Zeman; Horst Helbig; Maria-Andreea Gamulescu
Journal: Int Ophthalmol Date: 2017-01-21 Impact factor: 2.031

3. Long-term effect of intravitreal injection of anti-VEGF agent for visual acuity and chorioretinal atrophy progression in myopic choroidal neovascularization.

Authors: Akio Oishi; Kenji Yamashiro; Akitaka Tsujikawa; Sotaro Ooto; Hiroshi Tamura; Isao Nakata; Masahiro Miyake; Nagahisa Yoshimura
Journal: Graefes Arch Clin Exp Ophthalmol Date: 2012-04-19 Impact factor: 3.117

4. Idiopathic juxtafoveolar retinal telangiectasis: a current review.

Authors: Sawsan R Nowilaty; Hanan N Al-Shamsi; Wajeeha Al-Khars
Journal: Middle East Afr J Ophthalmol Date: 2010-07

Review 5. Macular telangiectasia type 2.

Authors: Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal: Prog Retin Eye Res Date: 2012-12-03 Impact factor: 21.198

6. Macular telangiectasia type 2 accompanied by solitary retinal astrocytic hamartoma (case report).

Authors: Martin Pencak; Jan Krasny; Miroslav Veith; Magdalena Vokrojova
Journal: BMC Ophthalmol Date: 2016-11-11 Impact factor: 2.209

6 in total